Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Isis magazine Stories

2012-08-06 02:26:05

CARLSBAD, Calif., Aug. 6, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma net operating income of $6.2 million for the three months ended June 30, 2012 and a pro forma net operating loss (NOL) of $10.0 million for the six months ended June 30, 2012 compared to a pro forma NOL of $11.6 million and $24.9 million for the same periods in 2011. The significant improvement in the Company's operating results was driven primarily by the $25 million milestone...

2012-05-08 02:27:23

CARLSBAD, Calif., May 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $16.2 million for the first quarter of 2012 compared to a pro forma NOL of $13.4 million for the same period in 2011. The Company ended the first quarter of 2012 with nearly $334 million in cash. "Already in 2012, we have had multiple important accomplishments. Our partners at Genzyme submitted the KYNAMRO(TM) new drug application (NDA) to the...

2012-02-29 06:00:00

CARLSBAD, Calif., Feb. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2011 financial results and reviewed the highlights of the year. Isis finished 2011 with a pro forma net operating loss (NOL) of $61.3 million compared to a pro forma NOL of $36.2 million for 2010. The Company finished 2011 with nearly $344 million in cash. On a GAAP basis, Isis reported a loss from operations of $18.6 million and $71.1 million for the three and twelve months ended...

2011-10-12 08:00:00

PROVIDENCE, R.I., Oct. 12, 2011 /PRNewswire/ -- Isis Biopolymer announced the appointment of Chris Hobson as its new president and chief executive officer, effective October 1, 2011. Concurrently, Mr. Hobson has been appointed to the Isis Biopolymer board of directors. Isis Biopolymer, based in Providence, RI, has pioneered advancements in polymer chemistry, miniaturization and electronics packaging to provide "active" transdermal infusion technology for the next generation delivery of...

2011-08-04 15:01:00

CARLSBAD, Calif., Aug. 4, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended June 30, 2011. The Company finished the second quarter of 2011 with a pro forma net operating loss (NOL) of $11.6 million and $24.9 million for the three and six months ended June 30, 2011, respectively, compared to a pro forma NOL of $15.5 million and $17.1 million for the same periods in 2010. The Company finished the second quarter of...

2011-02-28 15:00:00

CARLSBAD, Calif., Feb. 28, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2010 financial results and reviewed the highlights of the year. Isis improved upon its 2010 financial guidance with a pro forma net operating loss (NOL) of $36.2 million, which is significantly better than the mid to high $40 million range pro forma NOL the Company projected. Isis also exceeded its cash guidance by ending 2010 with $472.4 million of cash, cash equivalents and...

2010-11-04 15:00:00

CARLSBAD, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended September 30, 2010. The Company finished the third quarter of 2010 with a pro forma net operating loss (NOL) of $6.0 million and $23.1 million for the three and nine months ended September 30, 2010, respectively, compared to a pro forma net operating loss of $6.9 million and $6.1 million for the same periods in 2009. On a GAAP...

2010-08-09 06:00:00

CARLSBAD, Calif., Aug. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009....

2010-05-06 06:00:00

CARLSBAD, Calif., May 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended March 31, 2010. The Company finished the first quarter of 2010 with a pro forma net operating loss (NOL) of $1.5 million compared to pro forma net operating income of $2.1 million in the first quarter of 2009. On a GAAP basis, Isis reported a net operating loss of $4.9 million for the three months ended March 31, 2010, compared to...

2010-03-01 06:00:00

CARLSBAD, Calif., March 1 /PRNewswire-FirstCall/ -- Reports Second Consecutive Year of Pro Forma Net Income Achieves All 2009 Financial Guidance Metrics Conference Call Webcast Monday, March 1, 8:30 a.m. EST at www.isispharm.com Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of...